| Literature DB >> 23695675 |
Catherine Vilchèze1, Travis Hartman, Brian Weinrick, William R Jacobs.
Abstract
Drugs that kill tuberculosis more quickly could shorten chemotherapy significantly. In Escherichia coli, a common mechanism of cell death by bactericidal antibiotics involves the generation of highly reactive hydroxyl radicals via the Fenton reaction. Here we show that vitamin C, a compound known to drive the Fenton reaction, sterilizes cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis. While M. tuberculosis is highly susceptible to killing by vitamin C, other Gram-positive and Gram-negative pathogens are not. The bactericidal activity of vitamin C against M. tuberculosis is dependent on high ferrous ion levels and reactive oxygen species production, and causes a pleiotropic effect affecting several biological processes. This study enlightens the possible benefits of adding vitamin C to an anti-tuberculosis regimen and suggests that the development of drugs that generate high oxidative burst could be of great use in tuberculosis treatment.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23695675 PMCID: PMC3698613 DOI: 10.1038/ncomms2898
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Minimum inhibitory concentration (MIC) of vitamin C against Gram-positive and Gram-negative bacterial species.
| Strain | MIC (mM) |
|---|---|
| 1 | |
| H37Rv Δ | 0.015 |
| H37Rv Δ | 1 |
| 8 | |
| 8 | |
| 8 | |
| 16 | |
| Methicillin-resistant | >32 |
| 32 | |
| 16 | |
| >32 |
Figure 1Vitamin C sterilizes drug-susceptible and drug-resistant M. tuberculosis strains
(a) M. tuberculosis H37Rv cultures grown to an OD600nm of ≈ 0.75 were diluted 1/20 and treated with increasing amounts of vitamin C (VC, from 0.1 mM to 4 mM). 1 mM* represents an experiment where 1 mM of vitamin C was added to the culture daily for the first 4 days of treatment. (b) M. tuberculosis H37Rv was treated with INH (7 µM, 20× MIC), vitamin C (1 or 4 mM) and a combination of INH and vitamin C (1 and 4 mM). (c) mc24997, a RIF- and INH-resistant M. tuberculosis H37Rv strain was treated with vitamin C (4 mM). (d) Vitamin C (4 mM) was added to a drug-susceptible strain (V9124) and to an extensively drug-resistant strain (TF275) of M. tuberculosis from the Kwa-Zulu Natal province of South Africa. Growth was followed and CFUs were determined by plating 10-fold serial dilutions and incubating the plates at 37°C for 4 weeks. The experiments were done at least in triplicate and the average with standard deviation is plotted.
Transcriptional profile of vitamin C-treated M. tuberculosis reveals a possible displacement of divalent cations.
| Gene | Annotation | Cl | FC | Gene | Annotation | Cl | FC |
|---|---|---|---|---|---|---|---|
| Phosphatidylserine decarboxylase | 1 | 3.11 | Polyketide synthetase | 1 | −2.30 | ||
| Succinyl-diaminopimelate desuccinylase | 7 | 2.54 | Acetyl-CoA acetyltransferase | 1 | −2.30 | ||
| Type I restriction system DNA methylase | 2 | 2.01 | Possible glycosyl hydrolase | 7 | −2.10 | ||
| Probable Lytb-related protein | 3 | 1.98 | F420 synthase | 7 | −2.06 | ||
| Chorismate mutase | 7 | 1.91 | Probable endonuclease VIII | 7 | −2.04 | ||
| Transcriptional regulatory protein | 7 | 1.61 | Possible mycolic acid synthase | 1 | −1.99 | ||
| Possible oxidoreductase | 7 | 1.57 | Possible amidotransferase | 7 | −1.93 | ||
| Probable acetyl-/propionyl-CoA carboxylase | 1 | 1.55 | Probable phosphomannomutase | 7 | −1.83 | ||
| Cysteinyl-tRNA synthetase | 2 | 1.54 | Probable glycogen phosphorylase | 7 | −1.62 | ||
| Probable transcriptional regulatory protein | 9 | 1.53 | Probable hemoglobin | 7 | −1.56 | ||
| Probable esterase/lipase | 7 | 1.42 | Carbamoyl-phosphate synthase small subunit | 7 | −1.53 | ||
| Nicotinic acid mononucleotide adenyltransferase | 7 | 1.41 | Probable hydroxylaminobenzene mutase | 7 | −1.45 | ||
| Urease alpha subunit (urea amidohydrolase) | 7 | 1.41 | Mce-family protein | 0 | −1.39 | ||
| Possible resuscitation-promoting factor | 3 | 1.38 | Alkyl hydroperoxide reductase | 0 | −1.39 | ||
| Probable monooxygenase | 7 | 1.32 | Probable glycosyltransferase | 7 | −1.34 | ||
| Dimethyladenosine transferase | 2 | 1.29 | 50s ribosomal protein l33 | 2 | −1.27 | ||
| Haloalkane dehalogenase | 7 | 1.26 | Possible oxidoreductase | 7 | −1.25 | ||
| Probable PhoH-like protein | 7 | 1.24 | Possible epoxide hydrolase | 0 | −1.23 | ||
| N-acetyl-gamma-glutamyl-phosphate reductase | 7 | 1.23 | Anti-anti-sigma factor | 2 | −1.23 | ||
| Possible cysteine synthase A | 7 | 1.15 | Probable conserved lipoprotein | 3 | −1.19 | ||
| Probable urease accessory protein | 7 | 1.15 | Probable iron-sulfur-binding reductase | 7 | −1.19 | ||
| Probable precorrin-4 C11-methyltransferase | 7 | 1.14 | Probable oxidoreductase | 7 | −1.11 | ||
| Possible acyl-CoA dehydrogenase | 1 | 1.13 | Iron-dependent repressor and activator | 9 | −1.10 | ||
| Mce-family protein | 0 | 1.13 | Two-component response transcriptional regulatory | 9 | −1.10 | ||
| Biotin synthase | 7 | 1.07 | Cysteinyl-tRNA synthetase | 7 | −1.09 | ||
| cytochrome biogenesis protein | 7 | 1.07 | Molybdenum cofactor biosynthesis protein | 7 | −1.09 | ||
| Arsenic-transport integral membrane protein | 3 | 1.07 | Possible glycosyl transferase | 7 | −1.06 | ||
| Probable sugar transferase | 7 | 1.06 | Probable iron-sulfur-binding reductase | 7 | −1.19 | ||
| Probable electron transfer flavoprotein | 7 | 1.06 | Probable oxidoreductase | 7 | −1.11 | ||
| Probable cytochrome p450 141 | 7 | 1.04 | Iron-dependent repressor and activator | 9 | −1.10 | ||
| Probable polyprenyl-diphosphate synthase | 1 | 1.03 | Two-component response transcriptional regulatory | 9 | −1.10 | ||
| methylenetetrahydrofolate dehydrogenase | 7 | 1.03 | Cysteinyl-tRNA synthetase | 7 | −1.09 | ||
| Conserved hypothetical ALA-, PRO-rich protein | 7 | 1.01 | Molybdenum cofactor biosynthesis protein | 7 | −1.09 | ||
| Ferrochelatase | 7 | 0.98 | Possible glycosyl transferase | 7 | −1.06 | ||
| Probable cytochrome P450 128 | 7 | 0.98 | |||||
| Siderophore utilization protein | 7 | 0.98 | |||||
| Acyl carrier protein | 1 | 0.98 | |||||
| Probable inositol-monophosphatase | 7 | 0.97 | |||||
| Enoyl-CoA hydratase | 1 | 0.97 | |||||
FC: log2 Fold Change
Cl: Classification, based on the Tuberculist website (http://genolist.pasteur.fr/TubercuList/), stands for: 0, virulence, detoxification, adaptation; 1, lipid metabolism; 2, information pathways; 3, cell wall and cell processes; 7, intermediary metabolism and respiration; 9, regulatory proteins. The genes highlighted in bold are encoding enzymes containing divalent cations in their active sites. The experiment was done in triplicate.
Figure 2Vitamin C affects iron concentrations in M. tuberculosis
Iron bound to proteins, total free iron (ferric + ferrous) and free ferrous ion concentrations were measured as described in Methods. Iron concentrations are given relative to untreated. M. tuberculosis mc26230 treated with (a) 1 mM or 4 mM vitamin C (VC) for 3 days, (b) vitamin C (4 mM) for 1, 2, 3, or 4 days, (c) DFO (100 mg/L, 152 µM), vitamin C (4 mM) or a combination of both for 3 days. The experiments were done in triplicate and the average with standard deviation is plotted.
Figure 3The effect of vitamin C is dependent on iron concentration
(a) The iron scavenger deferoxamine (DFO) inhibits the bactericidal activity of vitamin C (VC) against M. tuberculosis H37Rv. M. tuberculosis H37Rv cultures were grown to an OD600nm of ≈0.7, diluted 1/20 and treated with with DFO (100 mg/L, 152 µM) and with or without 4 mM vitamin C. Growth was followed by plating for CFUs over time. (b) The growth of M. tuberculosis in Roisin medium with and without additional ferric ion (Fe, ferric ammonium citrate (0.04 g/l)) and treated or not with 4 mM vitamin C was followed by plating for CFUs over time. The experiments were done in triplicate and the average with standard deviation is plotted.
Figure 4Vitamin C increases reactive oxygen species levels and DNA damage in M. tuberculosis
(a) M. tuberculosis mc26230 cells treated with low (0.4 mM) or high (4 mM) concentrations of vitamin C (VC) or with 4 mM of vitamin E (VE) were stained with dihydroethidium. Total reactive oxygen species concentrations were measured by flow cytometry as described in Methods and followed for 4 days. (b) The % of double stranded DNA breaks were followed over the course of 9 days in M. tuberculosis mc26230 treated with vitamin C (4 mM) or vitamin E (4 mM). The experiments were done in triplicate and the average with standard deviation is plotted.
Figure 5Vitamin C acts as a pro-oxidant in M. tuberculosis
(a) M. tuberculosis mc26230 was grown under aerobic conditions and then shifted to an anaerobic chamber (<0.0001% O2, 5% CO2, 10% H2, 85% N2). After 24 h, the culture was diluted 1/20 with hypoxic media and treated with 4 mM vitamin C (VC). Aliquots were taken at indicated time and plated to determine CFUs. Plates were incubated in an aerobic incubator. (b) The mycothiol-deficient strain H37Rv ΔmshA, grown in Middlebrook 7H9 supplemented with OADC instead of ADS, was treated with 4 mM vitamin C. Growth was followed by plating for CFUs at different times. Both experiments were done in duplicate and the average with standard deviation is plotted.
Figure 6Vitamin C affects mycobacterial lipids
(a) Polar lipid analysis of M. tuberculosis H37Rv treated or not with vitamin C (4 mM) for 24 h followed by labeling with 14C-acetate for 22 h. Lipids were extracted and analyzed on thin-layer chromatography (TLC) as described in Methods. The same amount of cpm was spotted for each sample. The elution solvent used was CHCl3/MeOH/H2O (10/5/1; v/v/v). DPG, diphosphatidylglycerol; PE, phosphatidylethanolamine; P, unknown phospholipids; PI, phosphatidylinositol; Ac1/2PIM2, mono- and diacyl-phosphatidylinositol dimannosides; Ac2PIM6, phosphatidylinositol hexamannosides (based on[48]). (b) M. tuberculosis H37Rv was treated with vitamin C (VC, 4 mM) for 24 h and then labeled with 14C-acetate for 22 h. Fatty acid methyl esters (FAMEs) and mycolic acid methyl esters (MAMEs) were extracted and analyzed by TLC as described in Methods. The same amount of cpm was spotted for each sample. (c) Radiolabeled fatty acids used for TLC (b) were saponified and derivatized to UV-absorbing esters for HPLC analysis as described in Methods. (d) Distribution of fatty acids based on the integration of the signals from the HPLC chromatograms shown in (c) 14:0, myristic acid; 16:0, palmitic acid; 18:1, oleic acid; 18:0, stearic acid; 18:0–10Me, tuberculosteric acid; 20:0, eicosanoic acid; 22:0, behenic acid; 24:0, lignoceric acid; 26:0, hexacosanoic acid (e) NADH, NAD+, NADPH, and NADP+ concentrations were measured in M. tuberculosis treated with vitamin C (4 mM) for 3 days, as described in Methods. The experiments were done in triplicate. (f) Heatmap representation of the lipids the most differentially present in the control samples (M. tuberculosis mc26230) versus the samples treated with vitamin C (4 mM) for 3 days based on Waters MarkerLynx and Extended Statistics software analysis. In bold are compounds confirmed with standards, and in grey are hypothetical compounds based on m/z and retention time. The other compounds were identified using public mycobacterial lipid databases. The heatmap represents the average of three independent experiments.
Figure 7Schematic representation of the mechanism of action of vitamin C against M. tuberculosis
Vitamin C enters M. tuberculosis cells and reduces ferric ions to generate ferrous ions which, in presence of oxygen, will produce superoxide, hydrogen peroxide and hydroxyl radicals via the Harber-Weiss and Fenton reactions. The production of these reactive oxygen species leads to the DNA damage, alteration of lipids and redox balance.